Experimental drug enters human testing for Tough-to-Treat cancers
NCT ID NCT06515990
Summary
This is the first human trial of an experimental cancer drug called DM005. The study aims to find a safe and effective dose for patients with advanced solid tumors like lung and head/neck cancer that have stopped responding to standard treatments. Researchers will give the drug through an IV every three weeks to 136 participants and closely monitor for side effects and early signs of tumor response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, New South Wales, Australia
Contact
-
Henry Ford Cancer Institute
RECRUITINGDetroit, Michigan, 48202, United States
Contact
-
ICON Cancer Center
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact
-
Macquarie University Hospital
RECRUITINGNorth Ryde, New South Wales, Australia
Contact
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
Sarah Cannon Research Institute at Mary Crowley
RECRUITINGDallas, Texas, 75251, United States
Contact
Conditions
Explore the condition pages connected to this study.